Rephonic
Artwork for PHASE3
Radiopharmaceuticals
Life Sciences
Kidney Disease
Biotechnology
Cancer Vaccines
Chronic Kidney Disease
Australia
Cancer Treatment
Immunotherapy
Health Science
Technology
Investment
Kidney Health Australia
Cancer
Mrna
Clinical Trials
Polycystic Kidney Disease
Dialysis
Healthcare Policy
Technetium-99

A weekly podcast exploring medicine 4.0 as we launch into the 21st Century of health. Join us as we highlight the science and investment case for the different diseases and conditions that life sciences companies are trying to diagnose and cure.

PublishesWeeklyEpisodes16Foundeda year ago
Categories
Life SciencesScience

Listen to this Podcast

Artwork for PHASE3

Latest Episodes

Moderna and BioNTech are getting all of the attention with their phase 3 clinical trials for lung cancer and melanoma. But someone else is already further ahead.

French company Ose Immunotherapeutics has already done a phase 3 study for non small ... more

Cancer vaccines are an area that anyone who is anyone is getting into, but its a field led largely by academics, not-for–profits, and specialist researchers. So this week we go back to basics - science that is.

Australia may not have many cancer va... more

In some ways, cancer vaccines are a history of hype and hope, over success. But that hasnt stopped people from trying. In 2024, biotech CEOs are hoping that this time, its different.

Research houses are predicting significant market growth come 203... more

Cancer vaccines are a very niche section of cancer treatments. But two companies in Australia – the only two so far to go public with their work in this arena –are working on an even niche area within this. And one says their work is not a vaccine. T... more

Key Facts

Accepts Guests
Contact Information
Podcast Host

Similar Podcasts

People also subscribe to these shows.

Chanticleer
ChanticleerAustralian Financial Review

Recent Guests

Jeannie Jockin
Partner with venture investor OneVentures
OneVentures
Episode: VAXXED: And the winner is... with OneVentures and Ose Immunotherapeutics
Nicolas Poirier
CEO of Ose Immunotherapeutics
Ose Immunotherapeutics
Episode: VAXXED: And the winner is... with OneVentures and Ose Immunotherapeutics
Dr. Seth Cheetham
Molecular biologist leading mRNA cancer vaccine projects at Base
University of Queensland
Episode: VAXXED: Game on, with BASE and WEHI
Dr. Sharlan Nayak
Lab head at Walter and Eliza Hall Institute, focused on dendritic cell vaccines
Walter and Eliza Hall Institute
Episode: VAXXED: Game on, with BASE and WEHI
Chris Kallos
Analyst focusing on biotech investments
Episode: VAXXED: Boom or bust? With Chris Kallos and Pitt Street Research
Stuart Roberts
Co-founder of Pitt Street Research and biotech analyst
Pitt Street Research
Episode: VAXXED: Boom or bust? With Chris Kallos and Pitt Street Research
Matt Zeller
Country head of Novartis, involved in radiopharmaceutical development
Novartis
Episode: NUKED: Our nuclear future, with Novartis, Wilsons Advisory and Cyclotek
Dr. Melissa Benson
Equity Analyst at Wilsons Advisory
Wilsons Advisory
Episode: NUKED: Our nuclear future, with Novartis, Wilsons Advisory and Cyclotek
Sam Graf
Head of Innovation at Cyclotek, focusing on radiopharmaceutical delivery solutions
Cyclotek
Episode: NUKED: Our nuclear future, with Novartis, Wilsons Advisory and Cyclotek

Host

Rachel Williamson
Host of discussions integrating finance with advancements in life sciences, focusing on health innovations and investment opportunities.

Chart Rankings

How this podcast ranks in the Apple Podcasts, Spotify and YouTube charts.

Talking Points

Recent interactions between the hosts and their guests.

VAXXED: And the winner is... with OneVentures and Ose Immunotherapeutics
Q: How much pressure are you feeling to be the first one to get that market share?
Poiriere acknowledges the pressure but emphasizes the agility of their small biotech company.
VAXXED: And the winner is... with OneVentures and Ose Immunotherapeutics
Q: What about patients who don't respond to immunotherapy? What's the option for them?
Poiriere states they can design better vaccines with RNA or peptides, selecting patients more likely to respond to these innovations.
VAXXED: And the winner is... with OneVentures and Ose Immunotherapeutics
Q: How many more vaccines you think might actually make it to market compared to what they've estimated?
Jeannie believes that due to advancements in big data and the speed of analysis, the number of vaccines in development may be underestimated.
The Silent Killer: The sci-fi episode, with Certa Therapeutics and University of Sydney CTC
Q: What are your expectations of the burden of kidney disease due to climate change?
Kidney disease prevalence is expected to rise dramatically due to climate change, especially affecting agricultural workers in hot climates.
The Silent Killer: The sci-fi episode, with Certa Therapeutics and University of Sydney CTC
Q: What in your opinion can we expect from novel therapies in the future?
Groundbreaking therapies like GLP-1s will have a significant impact on mortality and treat a variety of metabolic diseases, indicating a shift in managing chronic conditions.

Audience Metrics

Listeners, social reach, demographics and more for this podcast.

Gender Skew
Location
Interests
Professions
Age Range
Household Income
Social Media Reach

Frequently Asked Questions About PHASE3

What is PHASE3 about and what kind of topics does it cover?

This podcast focuses on the intersection of medicine, investment, and the emerging capabilities within the life sciences sector. A notable emphasis is placed on innovations in cancer treatments and advanced therapies, particularly in areas like radiopharmaceuticals and kidney disease. Engaging interviews with industry experts, entrepreneurs, and researchers offer insights into new technologies, regulatory landscapes, and investment opportunities that shape the future of healthcare. The discussions reflect a commitment to understanding the complexities of medical advancements while highlighting actionable investment insights for the interested listener.

Where can I find podcast stats for PHASE3?

Rephonic provides a wide range of podcast stats for PHASE3. We scanned the web and collated all of the information that we could find in our comprehensive podcast database. See how many people listen to PHASE3 and access YouTube viewership numbers, download stats, audience demographics, chart rankings, ratings, reviews and more.

How many listeners does PHASE3 get?

Rephonic provides a full set of podcast information for three million podcasts, including the number of listeners. View further listenership figures for PHASE3, including podcast download numbers and subscriber numbers, so you can make better decisions about which podcasts to sponsor or be a guest on. You will need to upgrade your account to access this premium data.

What are the audience demographics for PHASE3?

Rephonic provides comprehensive predictive audience data for PHASE3, including gender skew, age, country, political leaning, income, professions, education level, and interests. You can access these listener demographics by upgrading your account.

How many subscribers and views does PHASE3 have?

To see how many followers or subscribers PHASE3 has on Spotify and other platforms such as Castbox and Podcast Addict, simply upgrade your account. You'll also find viewership figures for their YouTube channel if they have one.

Which podcasts are similar to PHASE3?

These podcasts share a similar audience with PHASE3:

1. The Readout Loud
2. Chanticleer
3. Equity Mates Investing Podcast
4. BioCentury This Week

How many episodes of PHASE3 are there?

PHASE3 launched a year ago and published 16 episodes to date. You can find more information about this podcast including rankings, audience demographics and engagement in our podcast database.

How do I contact PHASE3?

Our systems regularly scour the web to find email addresses and social media links for this podcast. We scanned the web and collated all of the contact information that we could find in our podcast database. But in the unlikely event that you can't find what you're looking for, our concierge service lets you request our research team to source better contacts for you.

Where can I see ratings and reviews for PHASE3?

Rephonic pulls ratings and reviews for PHASE3 from multiple sources, including Spotify, Apple Podcasts, Castbox, and Podcast Addict.

View all the reviews in one place instead of visiting each platform individually and use this information to decide if a show is worth pitching or not.

How do I access podcast episode transcripts for PHASE3?

Rephonic provides full transcripts for episodes of PHASE3. Search within each transcript for your keywords, whether they be topics, brands or people, and figure out if it's worth pitching as a guest or sponsor. You can even set-up alerts to get notified when your keywords are mentioned.

What guests have appeared on PHASE3?

Recent guests on PHASE3 include:

1. Jeannie Jockin
2. Nicolas Poirier
3. Dr. Seth Cheetham
4. Dr. Sharlan Nayak
5. Chris Kallos
6. Stuart Roberts
7. Matt Zeller
8. Dr. Melissa Benson

To view more recent guests and their details, simply upgrade your Rephonic account. You'll also get access to a typical guest profile to help you decide if the show is worth pitching.

Find and pitch the right podcasts

We help savvy brands, marketers and PR professionals to find the right podcasts for any topic or niche. Get the data and contacts you need to pitch podcasts at scale and turn listeners into customers.
Try it free for 7 days